Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRBP | US
-0.90
-4.48%
Healthcare
Biotechnology
30/06/2024
04/10/2024
19.21
20.07
20.34
18.89
Corbus Pharmaceuticals Holdings Inc. a biopharmaceutical company develops products to defeat serious illness. It develops CRB-701 an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE) which is in Phase I clinical trial; CRB-601 an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913 an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum an oral molecule that selectively activates cannabinoid receptor type 2 (CB2) which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery LLC to develop and commercialize the licensed products including the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
329.5%1 month
229.4%3 months
150.4%6 months
120.0%-
-
2.01
0.12
0.10
0.17
8.26
-
-39.60M
231.36M
231.36M
-
-
-
-100.00
-51.78
4.90
12.59
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
6.33
Range1M
41.90
Range3M
44.90
Rel. volume
0.39
Price X volume
9.31M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Poseida Therapeutics Inc | PSTX | Biotechnology | 2.61 | 253.52M | -1.14% | n/a | 137.55% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 3.82 | 252.91M | -1.29% | n/a | 3.53% |
Amarin Corporation plc | AMRN | Biotechnology | 0.6058 | 249.09M | 0.30% | n/a | 1.47% |
2seventy bio Inc | TSVT | Biotechnology | 4.81 | 247.70M | 0.00% | n/a | 107.07% |
Nanobiotix S.A | NBTX | Biotechnology | 5.19 | 246.03M | 0.00% | n/a | -2742.14% |
Adaptimmune Therapeutics plc | ADAP | Biotechnology | 0.951 | 243.21M | 8.72% | n/a | 49.18% |
Nektar Therapeutics | NKTR | Biotechnology | 1.32 | 242.98M | -0.75% | n/a | 275.58% |
JSPR | JSPR | Biotechnology | 16.08 | 242.89M | -5.47% | n/a | 2.31% |
Gossamer Bio Inc | GOSS | Biotechnology | 1.07 | 242.06M | 1.90% | n/a | 243.93% |
Enanta Pharmaceuticals Inc | ENTA | Biotechnology | 11.41 | 241.76M | 1.42% | n/a | 151.88% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.33 | 5.20M | 0.03% | n/a | 0.97% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.17 | 0.76 | Cheaper |
Ent. to Revenue | 8.26 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.01 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 150.40 | 74.67 | Riskier |
Debt to Equity | 0.12 | -1.82 | Expensive |
Debt to Assets | 0.10 | 0.26 | Cheaper |
Market Cap | 231.36M | 3.73B | Emerging |